Giotopoulos, G
Chan, W-I
Horton, S J
Ruau, D
Gallipoli, P
Fowler, A
Crawley, C
Papaemmanuil, E
Campbell, P J
Göttgens, B
Van Deursen, J M
Cole, P A
Huntly, B J P
Article History
Received: 30 September 2014
Revised: 27 January 2015
Accepted: 5 February 2015
First Online: 20 April 2015
Competing interests
: PA Cole is a cofounder, equity holder and paid consultant for Acylin Therapeutics which is developing p300 HAT inhibitors.